<DOC>
	<DOCNO>NCT00057343</DOCNO>
	<brief_summary>The purpose study provide treatment patient relapse NHL refractory NHL , determine effectiveness safety Zevalin Rituxan regimens Rituxan therapy alone disease .</brief_summary>
	<brief_title>Safety Efficacy Zevalin Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Summary major inclusion exclusion criterion . Other Safety criterion need meet . Histologically confirm , relapse refractory CD20+ follicular Bcell NHL within 12 month Study Day 1 ( without clinical evidence transformation ) . NHL must require treatment determined increase overall tumor size . The presence B symptom , and/or presence mass cause ongoing clinical symptom . Bidimensionally measurable disease meeting minimum requirement least 1 lesion &gt; /= 2.0 cm single dimension . No lymphoma therapy 3 week prior Study Day 1 . Patients must recover toxicity associate prior surgery , radiation therapy , chemotherapy , immunotherapy . Signed IRBapproved informed consent . Greater 18 year age . Expected survival &gt; /= 3 month . WHO performance status &lt; /= 2 . Acceptable hematologic status , liver function , renal function , pulmonary function . Female patient pregnant lactate . Men woman reproductive potential following accept birth control method . Patients impair bone marrow reserve , may indicate prior myeloablative therapy autologous bone marrow transplantation ( ABMT ) peripheral blood stem cell ( PBSC ) rescue . Prior radioimmunotherapy , include Zevalin regimen . Prior immunotherapy , include Rituxan therapy within 6 month Study Day 1 . Rituxanrefractory ( response recent Rituxancontaining regimen , TTP &lt; 6 month ) . Presence CNS lymphoma . Patients chronic lymphocytic leukemia ( CLL ) . Known history HIV AIDS . Serious nonmalignant disease infection Major surgery , diagnostic surgery , within 4 week Study Day 1 . Patients receive investigational product within 4 week Study Day 1 patient may experience longterm toxicity previous investigational therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>